LAURA BLUE: Open Payments
NPI 1154925535 · WAIANAE, HI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,246 in 51 payments from 10 companies in 2025. Trend: 2023 $99 · 2024 $455 · 2025 $1,246
Food & beverage: $1,246
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 18 | $378 |
| ABBVIE INC. | 8 | $184 |
| Otsuka America Pharmaceutical, Inc. | 5 | $180 |
| Neurocrine BioSciences, Inc. | 6 | $154 |
| Janssen Pharmaceuticals, Inc | 4 | $100 |
| Lundbeck LLC | 3 | $74 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $55 |
| E.R. Squibb & Sons, L.L.C. | 2 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $43 |
| Vanda Pharmaceuticals Inc. | 1 | $29 |
Products named: ARISTADA, VRAYLAR, INGREZZA, ABILIFY MAINTENA, LYBALVI, REXULTI, INVEGA SUSTENNA, CAPLYTA.
Industry payments across HI — which companies pay providers there.
